scispace - formally typeset
Search or ask a question
Institution

University of Paris

EducationParis, France
About: University of Paris is a education organization based out in Paris, France. It is known for research contribution in the topics: Population & Transplantation. The organization has 102426 authors who have published 174180 publications receiving 5041753 citations. The organization is also known as: Sorbonne.


Papers
More filters
Journal ArticleDOI
TL;DR: These two phase 3 studies show the efficacy and safety of canakinumab in systemic JIA with active systemic features, and among the 100 patients who underwent randomization in the withdrawal phase, the risk of flare was lower among patients who continued to receive canakinUMab than among those who were switched to placebo.
Abstract: A B S T R AC T BACKGROUND Interleukin-1 is pivotal in the pathogenesis of systemic juvenile idiopathic arthritis (JIA). We assessed the efficacy and safety of canakinumab, a selective, fully human, anti–interleukin-1β monoclonal antibody, in two trials. METHODS In trial 1, we randomly assigned patients, 2 to 19 years of age, with systemic JIA and active systemic features (fever; ≥2 active joints; C-reactive protein, >30 mg per liter; and glucocorticoid dose, ≤1.0 mg per kilogram of body weight per day), in a double-blind fashion, to a single subcutaneous dose of canakinumab (4 mg per kilo gram) or placebo. The primary outcome, termed adapted JIA ACR 30 response, was defined as improvement of 30% or more in at least three of the six core criteria for JIA, worsening of more than 30% in no more than one of the criteria, and resolution of fever. In trial 2, after 32 weeks of open-label treatment with canakinumab, pa tients who had a response and underwent glucocorticoid tapering were randomly assigned to continued treatment with canakinumab or to placebo. The primary outcome was time to flare of systemic JIA. RESULTS At day 15 in trial 1, more patients in the canakinumab group had an adapted JIA ACR 30 response (36 of 43 [84%], vs. 4 of 41 [10%] in the placebo group; P<0.001). In trial 2, among the 100 patients (of 177 in the open-label phase) who underwent randomization in the withdrawal phase, the risk of flare was lower among patients who continued to receive canakinumab than among those who were switched to pla cebo (74% of patients in the canakinumab group had no flare, vs. 25% in the pla

611 citations

Journal ArticleDOI
TL;DR: Increased IL-6 production by sc adipose cells might participate to the insulin-resistant state observed in human obesity, suggesting that locally secreted IL- 6 could act on adipocytes by an autocrine/paracrine mechanism.
Abstract: Obesity and type 2 diabetes are associated with insulin resistance, the mechanisms of which remain poorly understood. A significant correlation between circulating IL-6 level and insulin sensitivity has recently been found in humans. Because adipose tissue could be a significant source of IL-6, we analyzed the relationship between the levels of adipose tissue IL-6 and insulin action in vivo, during a hyperinsulinemic normoglycemic clamp, and in vitro by measuring glucose transport in adipocytes from 12 obese subjects with (n = 7) or without (n = 5) diabetes. We observed an inverse correlation between adipose tissue IL-6 content and maximal insulin-responsiveness measured in vivo (P < 0.02) and in vitro (P < 0.02). Conversely, there was no significant correlation between these two later parameters and adipose tissue leptin or tumor necrosis factor-alpha protein contents. Furthermore, we showed, for the first time, the presence of immunoreactive IL-6 receptors in the plasma membrane of human abdominal sc adipocytes. This suggests that locally secreted IL-6 could act on adipocytes by an autocrine/paracrine mechanism. In conclusion, increased IL-6 production by sc adipose cells might participate to the insulin-resistant state observed in human obesity.

610 citations

Journal ArticleDOI
Stephen Anthony Eales1, Loretta Dunne2, David L. Clements3, Asantha Cooray4, G. de Zotti5, G. de Zotti6, Simon Dye1, Rob Ivison7, Matt J. Jarvis8, Guilaine Lagache9, Guilaine Lagache10, Steve Maddox2, Mattia Negrello11, Steve Serjeant11, Mark Thompson8, E. van Kampen12, Alexandre Amblard4, Paola Andreani12, Maarten Baes13, Alexandre Beelen9, Alexandre Beelen10, George J. Bendo3, Dominic J. Benford14, Dominic J. Benford12, Frank Bertoldi15, Frank Bertoldi13, James J. Bock16, D. G. Bonfield8, Alessandro Boselli17, C. Bridge9, V. Buat17, Denis Burgarella17, Raymond G. Carlberg18, Antonio Cava, Pierre Chanial3, S. Charlot19, N. Christopher20, Peter Coles1, Luca Cortese1, Aliakbar Dariush1, E. da Cunha21, Gavin Dalton22, Gavin Dalton20, Luigi Danese23, Helmut Dannerbauer23, Simon P. Driver, James Dunlop7, Lulu Fan18, Duncan Farrah18, David T. Frayer16, Carlos S. Frenk24, James E. Geach24, Jonathan P. Gardner14, Haley Louise Gomez1, J. González-Nuevo18, Eduardo Gonzalez-Solares25, Matthew Joseph Griffin1, Martin J. Hardcastle8, Evanthia Hatziminaoglou12, D. Herranz26, David H. Hughes, Edo Ibar7, Woong-Seob Jeong27, Cedric G. Lacey24, Andrea Lapi28, Andy Lawrence7, Myung Gyoon Lee29, Lerothodi Leonard Leeuw28, Jochen Liske12, M. López-Caniego23, Th. Müller23, Kirpal Nandra3, P. Panuzzo30, Andreas Papageorgiou1, G. Patanchon30, John A. Peacock7, C. P. Pearson22, Steven Phillipps, Michael Pohlen1, Cristina Popescu31, Steve Rawlings20, E. E. Rigby2, M. Rigopoulou20, Aaron S. G. Robotham32, Giulia Rodighiero5, Anne E. Sansom31, Benjamin L. Schulz, Douglas Scott33, D. J. B. Smith2, B. Sibthorpe7, Ian Smail24, Jamie Stevens8, William J. Sutherland34, Tsutomu T. Takeuchi35, Jonathan Tedds36, P. Temi37, Richard J. Tuffs23, Markos Trichas3, Mattia Vaccari5, Ivan Valtchanov38, P. van der Werf39, Aprajita Verma20, J. Vieria39, Catherine Vlahakis39, Glenn J. White11, Glenn J. White22 
TL;DR: The Herschel ATLAS project as discussed by the authors is the largest open-time key project that will be carried out on the Herschel Space Observatory, and it will survey 570 deg2 of the extragalactic sky, 4 times larger than all the other Herschel extragala surveys combined, in five far-infrared and submillimeter bands.
Abstract: The Herschel ATLAS is the largest open-time key project that will be carried out on the Herschel Space Observatory. It will survey 570 deg2 of the extragalactic sky, 4 times larger than all the other Herschel extragalactic surveys combined, in five far-infrared and submillimeter bands. We describe the survey, the complementary multiwavelength data sets that will be combined with the Herschel data, and the six major science programs we are undertaking. Using new models based on a previous submillimeter survey of galaxies, we present predictions of the properties of the ATLAS sources in other wave bands.

610 citations

Journal ArticleDOI
TL;DR: Among patients with newly diagnosed multiple myeloma who were ineligible for autologous stem-cell transplantation, the risk of disease progression or death was significantly lower among those who received daratumumab plus lenalidomide and dexamethasone than among thosewho received lenalidmide and Dexameth asone alone.
Abstract: Background Lenalidomide plus dexamethasone is a standard treatment for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem-cell transplantation. We sought...

609 citations

Journal ArticleDOI
TL;DR: Despite somewhat prolonged progression‐free survival, treatment with lomustine plus bevacizumab did not confer a survival advantage over treatment with LOMustine alone in patients with progressive glioblastoma.
Abstract: BACKGROUND: Bevacizumab is approved for the treatment of patients with progressive glioblastoma on the basis of uncontrolled data. Data from a phase 2 trial suggested that the addition of bevacizumab to lomustine might improve overall survival as compared with monotherapies. We sought to determine whether the combination would result in longer overall survival than lomustine alone among patients at first progression of glioblastoma. METHODS: We randomly assigned patients with progression after chemoradiation in a 2:1 ratio to receive lomustine plus bevacizumab (combination group, 288 patients) or lomustine alone (monotherapy group, 149 patients). The methylation status of the promoter of O6methylguanine–DNA methyltransferase (MGMT) was assessed. Healthrelated quality of life and neurocognitive function were evaluated at baseline and every 12 weeks. The primary end point of the trial was overall survival. RESULTS: A total of 437 patients underwent randomization. The median number of 6week treatment cycles was three in the combination group and one in the monotherapy group. With 329 overall survival events (75.3%), the combination therapy did not provide a survival advantage; the median overall survival was 9.1 months (95% confidence interval [CI], 8.1 to 10.1) in the combination group and 8.6 months (95% CI, 7.6 to 10.4) in the monotherapy group (hazard ratio for death, 0.95; 95% CI, 0.74 to 1.21; P=0.65). Locally assessed progression-free survival was 2.7 months longer in the combination group than in the monotherapy group: 4.2 months versus 1.5 months (hazard ratio for disease progression or death, 0.49; 95% CI, 0.39 to 0.61; P<0.001). Grade 3 to 5 adverse events occurred in 63.6% of the patients in the combination group and 38.1% of the patients in the monotherapy group. The addition of bevacizumab to lomustine affected neither healthrelated quality of life nor neurocognitive function. The MGMT status was prognostic. CONCLUSIONS: Despite somewhat prolonged progressionfree survival, treatment with lomustine plus bevacizumab did not confer a survival advantage over treatment with lomustine alone in patients with progressive glioblastoma. (Funded by an unrestricted educational grant from F. Hoffmann–La Roche and by the EORTC Cancer Research Fund; EORTC 26101 ClinicalTrials.gov number, NCT01290939; EudraCT number, 201002321830.)

609 citations


Authors

Showing all 102613 results

NameH-indexPapersCitations
Guido Kroemer2361404246571
David H. Weinberg183700171424
Paul M. Thompson1832271146736
Chris Sander178713233287
Sophie Henrot-Versille171957157040
Richard H. Friend1691182140032
George P. Chrousos1691612120752
Mika Kivimäki1661515141468
Martin Karplus163831138492
William J. Sandborn1621317108564
Darien Wood1602174136596
Monique M.B. Breteler15954693762
Paul Emery1581314121293
Wolfgang Wagner1562342123391
Joao Seixas1531538115070
Network Information
Related Institutions (5)
Centre national de la recherche scientifique
382.4K papers, 13.6M citations

95% related

École Normale Supérieure
99.4K papers, 3M citations

94% related

Imperial College London
209.1K papers, 9.3M citations

93% related

Sapienza University of Rome
155.4K papers, 4.3M citations

93% related

University of Groningen
69.1K papers, 2.9M citations

93% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
202376
2022602
202116,433
202015,008
201911,047
20189,090